COO

Business Profile & Competitive Position

The Cooper Companies, Inc. operates in the Healthcare sector, specifically in the Medical – Instruments & Supplies industry. It is a global medical device company with headquarters in San Ramon, California, running two distinct business units. CooperVision develops, manufactures, and markets single-use, two-week, and monthly contact lenses plus specialty eye-care products, including silicone hydrogel lenses, myopia-management products such as the MiSight 1 day lens, orthokeratology lenses, and scleral lenses. CooperSurgical offers more than 600 products and services in fertility and women’s health, including devices for gynecology, obstetrics, contraception, and labor and delivery, along with cord blood/tissue storage, IVF support, donor gametes, cryopreservation, and genomic services.

The numbers behind the business suggest a company with pricing power but capital-heavy returns. The 13.5% net margin shows Cooper keeps a meaningful portion of each sales dollar after operating costs. The 6.9% ROE, however, is comparatively low for that margin level, which typically points to a large asset base, accumulated goodwill from acquisitions, or reinvestment that has not yet converted into high equity returns. That combination is consistent with a medical-device portfolio built through product development and strategic deals rather than a lean, high-leverage operator. MiSight 1 day holds a genuine differentiator: it is the only contact lens approved by the FDA, China’s NMPA, and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. Products are sold in over 130 countries and the company reports that its products positively impact more than fifty million lives each year. R&D employment across both segments totals approximately 500 people.

Financial Posture

Cooper Companies currently carries a $10.8 billion market capitalization and trades at a P/E ratio of 18.9. That valuation is modest by healthcare-growth standards and sits below the level often associated with premium medical-device darlings. Net margin of 13.5% is healthy, yet the 6.9% ROE implies that profits are spread across a substantial equity base, likely reflecting years of capital deployment in acquisitions, manufacturing scale, and global distribution. A beta of 0.82 means the stock historically moves less than the overall market; it is not a high-beta momentum name.

The current snapshot has the stock at $55.29, with a 50-day EMA of $67.13, meaning price is trading well below its recent trend. The RSI reads 25.6, which technicians would describe as deeply oversold. A debt figure is not provided in this data snapshot, so any leverage analysis should be checked against the company’s most recent balance sheet rather than inferred.

Strategic Priorities & Outlook

According to the company’s own most recent SEC 10-K filing, CooperVision is focused on driving greater worldwide market penetration of recently introduced products and expanding its presence in both existing and emerging markets. To support that growth, it is increasing investment in distribution and packaging capabilities. It is also investing to develop the myopia-management market by educating eye care practitioners, patients, and their families, a direct extension of the MiSight opportunity.

CooperSurgical expects to continue investing in its business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health. That language signals further M&A and cross-selling rather than a pure cost-cutting or cash-harvesting phase. The strategic posture is therefore one of top-line expansion through product penetration and acquisitions, even if that reinvestment pressure helps explain the modest ROE.

Macro & Geopolitical Exposure

As a Medical – Instruments & Supplies company with global distribution, Cooper faces a set of macro and geopolitical exposures common to the industry. Regulatory risk is front and center: contact lenses and surgical devices are cleared by the FDA and counterpart agencies worldwide, and changes in approval pathways or labeling requirements can alter launch timelines. Reimbursement policy matters for CooperSurgical products tied to fertility and women’s health procedures; shifts in public or private coverage can affect demand. Because products are sold in more than 130 countries, currency translation is a recurring factor in reported revenue and earnings. Trade policy, including tariffs on finished medical devices or on raw materials and packaging components, can influence costs. Supply-chain reliability is also relevant for single-use lenses, which require consistent resin, packaging, and sterile manufacturing inputs. Longer-term industry demand is tied to demographic trends such as rising myopia rates and evolving fertility patterns.

Recent Developments

September 18, 2026 was an unusually active news day for the stock. Four separate headlines hit the wires:

• Levi & Korsinsky issued a Cooper Companies (COO) Securities Investigation Notice through PR Newswire.
• Reuters reported that Jana Partners urged Cooper to replace its CEO and explore asset sales after performance setbacks.
• Barron’s published “Activist Calls for Cooper Cos. to Seek New CEO.”
• JANA Partners issued a letter to Cooper’s Board of Directors via PR Newswire.

This cluster of activist pressure coincides with the stock trading at $55.29, beneath the $67.13 50-day EMA and an RSI of 25.6, a combination that suggests the market had already been repricing the shares lower before the activist campaign became public. Whether the activist demands lead to management changes, asset sales, or strategic review remains to be seen, but the headlines clearly frame investor focus squarely on governance and portfolio restructuring.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Cooper Companies has beaten earnings estimates every single time, an 8/8 beat rate, with an average earnings surprise of 4.2%. A naive read of that streak might imply a reliably bullish post-earnings response, but the actual price action is far more mixed. The average 5-day price move after earnings across those quarters is -2.34%, which the data classifies as a “down” post-earnings drift.

The last four quarters illustrate the disconnect in real time:

• On September 9, 2026, the company reported EPS of $1.15 against a $1.12 estimate, a 2.7% beat. The stock nonetheless fell 14.67% the next day and 13.97% over the following five sessions.
• On June 4, 2026, EPS came in at $1.21 versus a $1.10 estimate, a 10% surprise. The stock rose 8.58% the next day and 8.85% over the next five sessions.
• On March 5, 2026, EPS was $1.10 against a $1.03 estimate, a 6.8% beat. The stock dropped 4.55% the next day and 10.82% over the following five sessions.
• On December 4, 2025, EPS was $1.15 versus a $1.11 estimate, a 3.6% beat. The stock gained 5.67% the next day and 6.59% over the next five sessions.

The takeaway is that earnings beats have not reliably produced positive follow-through. Forward-looking guidance, segment margin commentary, foreign-exchange impacts, and non-earnings headlines often outweigh the headline EPS surprise. The next scheduled report is December 3, 2026 after the close, with the consensus EPS estimate at $1.08.

For a deeper dive into how analysts, activist investors, and institutional models are weighing these factors, readers should review the full institutional verdict rather than relying on headline earnings streaks alone.